Trial Information
Comparison of Efficacy, Safety and Economic Outcomes Between Once-Daily Versus Twice-Daily Amikacin in Combination With Cloxacillin in Febrile Neutropenic Children
Fever: a single oral temperature of >/= 38.3 degrees C; or >/= 38.0 degrees C for >/= 1
hour.
Neutropenia: neutrophil count, < 500/cu mm or <1,000/cu mm with a predicted decrease to
<500/mm3.
Inclusion Criteria:
- Aged 1 year - 14 years
- A single oral temperature of >/= 38.3 degrees C; or >/= 38.0 degrees C for >/= 1
hour.
- Neutropenia: neutrophil count, < 500/cu mm or <1,000/cu mm with a predicted decrease
to <500/mm3.
- During the course of chemotherapy
Exclusion Criteria:
- History of amikacin or cloxacillin allergy
- Creatinine clearance < 30 ml/min/m2
- Central nervous system infection: meningitis or brain abscess
- History of hearing abnormality
- Severely ill: shock
- Chronic liver diseases or SGPT > 10 times of upper normal limit
- Received aminoglycoside within 14 days prior to enrolment
- Received any intravenous antibiotics within 7 days
- Cancer which is newly diagnosed or relapsed
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Afebrile within 5 days of the initial treatment regimen
Principal Investigator
Pope - Kosalaraksa, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Faculty of Medicine, Khon Kaen University
Authority:
Thailand: Khon Kaen University Ethics Committee for Human Research
Study ID:
HE44290
NCT ID:
NCT00129688
Start Date:
April 2002
Completion Date:
June 2004
Related Keywords:
- Neutropenia
- Cancer
- Fever
- febrile neutropenia
- once-daily
- amikacin
- cloxacillin
- children
- Neutropenia